The drug, currently in a phase 1b/2 clinical trial for small cell lung cancer, is a polymer nanoparticle formulation of SN-38
For 2026 onwards, CPHI and PMEC India are evolving into two distinct, specialized shows
Study published in laboratory investigation, the official journal of the United States and Canadian Academy of Pathology
Using a combination of blood and faecal samples, the service examines key biomarkers, including hereditary genetic status
Additional investments planned to expand the site’s capacity and capabilities to support growing manufacturing programs
Expands bioprocessing footprint across Asia
India's pharmaceutical sector is rapidly shifting from a generics-led foundation to an innovation-driven ecosystem
Grangemouth serves as PPS’s dedicated antibody-drug conjugate development and manufacturing hub
_256_384.png)
India presents one of the world’s largest untapped opportunities for neurovascular screening
Subscribe To Our Newsletter & Stay Updated
